Fintel reports that on November 5, 2024, William Blair downgraded their outlook for Marqeta (NasdaqGS:MQ) from Outperform to ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

Fly fishing enthusiasts seeking a once-in-a-lifetime experience in untouched wilderness will soon have a new destination: the ...

However, for William “Will” Blair, it is his passion. Known for his relentless pursuit of untouched rivers and wilderness settings, Will has built a career and a lifestyle centered around ...

Fintel reports that on October 30, 2024, William Blair downgraded their outlook for BioMarin Pharmaceutical (WBAG:BMRN) from Outperform to Market Perform. There are 1,150 funds or institutions ...

Altair Engineering (NASDAQ:ALTR – Free Report) had its price target boosted by Royal Bank of Canada from $90.00 to $113.00 in ...

Photo courtesy of Republic Services Inc. Chicago-based equities advisory firm William Blair has appointed equity research analyst Trevor Romeo to initiate coverage of three companies in the solid ...

Fintel reports that on September 18, 2024, William Blair initiated coverage of NVIDIA (WBAG:NVDA) with a Outperform recommendation. What is the Fund Sentiment? There are 6,506 funds or ...

William Blair Small-Mid Cap Growth Fund earns a Below Average Process Pillar rating. The process is strengthened by its parent firm's long-term risk-adjusted performance, as shown by the firm's ...

William Blair Small-Mid Cap Growth Fund earns a Below Average Process Pillar rating. The process is strengthened by its parent firm's long-term risk-adjusted performance, as shown by the firm's ...

The Fund seeks long-term capital appreciation. Under normal conditions, the Fund invests primarily in a diversified portfolio of equity securities, including common stocks and other forms of ...